The biotech company has several products  in development that target dermatological and gastrointestinal disorders.

In June 2016, Edesa licensed the rights to ASF-1096 for use in anorectal disorders from Cipher Pharmaceuticals. ASF-1096 is a Phase II candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders.